DK2074122T3 - Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer - Google Patents

Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer

Info

Publication number
DK2074122T3
DK2074122T3 DK07804890.7T DK07804890T DK2074122T3 DK 2074122 T3 DK2074122 T3 DK 2074122T3 DK 07804890 T DK07804890 T DK 07804890T DK 2074122 T3 DK2074122 T3 DK 2074122T3
Authority
DK
Denmark
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
DK07804890.7T
Other languages
English (en)
Other versions
DK2074122T5 (da
Inventor
Mitchell David Nambu
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabet Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK2074122T3 publication Critical patent/DK2074122T3/da
Publication of DK2074122T5 publication Critical patent/DK2074122T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
DK07804890.7T 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer DK2074122T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
DK2074122T3 true DK2074122T3 (da) 2011-08-15
DK2074122T5 DK2074122T5 (da) 2014-03-17

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07804890.7T DK2074122T5 (da) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer

Country Status (42)

Country Link
US (3) US7696213B2 (da)
EP (1) EP2074122B9 (da)
JP (1) JP4718637B2 (da)
KR (1) KR101099926B1 (da)
CN (1) CN101573358B (da)
AP (1) AP2710A (da)
AR (1) AR062785A1 (da)
AT (1) ATE514695T1 (da)
AU (1) AU2007297212B8 (da)
BR (1) BRPI0716749B8 (da)
CA (1) CA2663401C (da)
CL (1) CL2007002682A1 (da)
CR (1) CR10662A (da)
CU (1) CU23783B7 (da)
CY (1) CY1111911T1 (da)
DK (1) DK2074122T5 (da)
DO (1) DOP2009000039A (da)
EA (1) EA016388B1 (da)
ES (1) ES2366489T3 (da)
GE (1) GEP20115306B (da)
GT (1) GT200700077A (da)
HK (1) HK1138589A1 (da)
HN (1) HN2007000267A (da)
HR (1) HRP20110621T2 (da)
IL (1) IL197243A (da)
MA (1) MA30709B1 (da)
ME (1) MEP8009A (da)
MX (1) MX2009002927A (da)
MY (1) MY146420A (da)
NI (1) NI200900032A (da)
NO (1) NO342357B1 (da)
NZ (1) NZ575167A (da)
PE (1) PE20080670A1 (da)
PL (1) PL2074122T3 (da)
PT (1) PT2074122E (da)
RS (2) RS51927B (da)
SI (1) SI2074122T1 (da)
TN (1) TN2009000085A1 (da)
TW (1) TWI334353B (da)
UY (1) UY30588A1 (da)
WO (1) WO2008032162A1 (da)
ZA (1) ZA200901477B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51927B (en) 2006-09-15 2012-02-29 Pfizer Products Inc. PIRIDO (2,3-D) PIRIMIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS P13
US8513266B2 (en) * 2007-04-10 2013-08-20 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
EA018964B1 (ru) * 2007-04-11 2013-12-30 Экселиксис, Инк. СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
RU2508110C2 (ru) 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
EP2326628A1 (en) 2008-08-20 2011-06-01 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072939A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
JP2012504628A (ja) * 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
KR20140072028A (ko) 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
RU2717570C2 (ru) 2014-10-10 2020-03-24 Пфайзер Инк. Синергистические комбинации ауристана
AU2016272881C1 (en) 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
ES2922898T3 (es) 2016-07-06 2022-09-21 Univ Michigan Regents Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos
KR102236605B1 (ko) * 2016-08-15 2021-04-05 화이자 인코포레이티드 피리도피리미딘온 cdk2/4/6 억제제
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3813946B1 (en) 2018-06-15 2024-05-22 Janssen Pharmaceutica NV Rapamycin analogs and uses thereof
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
PT790997E (pt) 1994-11-14 2000-06-30 Warner Lambert Co 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
BR0017075A (pt) 2000-01-27 2002-11-05 Warner Lambert Co Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
CZ20022929A3 (cs) 2000-03-06 2003-02-12 Warner-Lambert Company 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
AU2002233706C1 (en) 2001-02-26 2005-12-22 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
ES2291630T3 (es) 2002-04-19 2008-03-01 Smithkline Beecham Corporation Nuevos compuestos.
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
SI1648889T1 (sl) 2003-07-11 2009-02-28 Warner Lambert Co Izetionatna sol selektivnega CDK4 inhibitorja
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PL1713806T3 (pl) 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
ES2292130T3 (es) * 2004-05-04 2008-03-01 Warner-Lambert Company Llc Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
EP1786817A1 (de) 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
RS51927B (en) 2006-09-15 2012-02-29 Pfizer Products Inc. PIRIDO (2,3-D) PIRIMIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS P13
EP2527330A1 (en) * 2007-03-14 2012-11-28 Exelixis, Inc. Inhibitors of the hedgehog pathway
EA018964B1 (ru) 2007-04-11 2013-12-30 Экселиксис, Инк. СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
JP2012504628A (ja) 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
UY30588A1 (es) 2008-05-02
CU20090040A7 (es) 2011-07-11
GT200700077A (es) 2009-08-03
PT2074122E (pt) 2011-08-24
AP2009004790A0 (en) 2009-04-30
US8633204B2 (en) 2014-01-21
IL197243A0 (en) 2009-12-24
MEP8009A (en) 2011-12-20
NO342357B1 (no) 2018-05-14
US20120309775A1 (en) 2012-12-06
CA2663401A1 (en) 2008-03-20
PE20080670A1 (es) 2008-06-14
KR20090040389A (ko) 2009-04-23
PL2074122T3 (pl) 2011-10-31
AU2007297212A1 (en) 2008-03-20
TWI334353B (en) 2010-12-11
US20080090801A1 (en) 2008-04-17
EA016388B1 (ru) 2012-04-30
NZ575167A (en) 2010-10-29
RS51927B (en) 2012-02-29
ATE514695T1 (de) 2011-07-15
BRPI0716749B8 (pt) 2021-05-25
NI200900032A (es) 2010-05-14
IL197243A (en) 2013-07-31
HRP20110621T1 (en) 2011-09-30
ES2366489T9 (es) 2013-12-27
DK2074122T5 (da) 2014-03-17
AP2710A (en) 2013-07-30
HRP20110621T2 (hr) 2013-12-06
DOP2009000039A (es) 2015-12-15
RS20090104A (en) 2010-06-30
JP4718637B2 (ja) 2011-07-06
NO20091141L (no) 2009-03-31
AU2007297212B8 (en) 2011-04-28
BRPI0716749A2 (pt) 2014-02-18
MA30709B1 (fr) 2009-09-01
CN101573358A (zh) 2009-11-04
HN2007000267A (es) 2011-02-25
GEP20115306B (da) 2011-10-10
EA200970207A1 (ru) 2009-08-28
AU2007297212B2 (en) 2011-04-14
CU23783B7 (es) 2012-02-15
SI2074122T1 (sl) 2011-10-28
MY146420A (en) 2012-08-15
CN101573358B (zh) 2012-05-30
WO2008032162A1 (en) 2008-03-20
EP2074122B9 (en) 2013-09-11
AR062785A1 (es) 2008-12-03
EP2074122A1 (en) 2009-07-01
KR101099926B1 (ko) 2011-12-28
JP2010503653A (ja) 2010-02-04
ZA200901477B (en) 2010-07-28
WO2008032162A8 (en) 2009-03-26
TW200820972A (en) 2008-05-16
CR10662A (es) 2009-04-17
BRPI0716749B1 (pt) 2020-10-06
US20100137279A1 (en) 2010-06-03
EP2074122B1 (en) 2011-06-29
US7696213B2 (en) 2010-04-13
TN2009000085A1 (fr) 2010-08-19
ES2366489T3 (es) 2011-10-20
CA2663401C (en) 2011-07-12
MX2009002927A (es) 2009-03-31
US8273755B2 (en) 2012-09-25
CL2007002682A1 (es) 2008-04-04
HK1138589A1 (en) 2010-08-27
CY1111911T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
DK2074122T3 (da) Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer
LTPA2016036I1 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1845978T3 (da) Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK1966202T3 (da) Heteroarylsubstituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-d]pyrimidiner som Januskinaseinhibitorer
DK1888580T3 (da) Pyrido[2,3-D]pyrimidiner, der er egnede som HCV-hæmmere, og fremgangsmåde til fremstillingen af disse
ATE415400T1 (de) Pyrazolopyridinderivate
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK1928879T3 (da) Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2229391T3 (da) Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
DK2049557T3 (da) 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK1945631T3 (da) 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer